Researchers found that the biomarkers have a 56% sensitivity and a 95% specificity.
Ciphergen Biosystems report that it has discovered four proteins that may be potential diagnostic markers for early-stage ovarian cancer. Along with collaborators, the researchers say that these four proteins in urine separate women with early cancer from healthy individuals with a sensitivity of 56% and a specificity of 95%.
To elucidate these findings, Ciphergen employed protein expression profiling methods to analyze urine samples from 400 women, including 288 women with epithelial ovarian cancer, 52 with early-stage disease, and 176 with late-stage disease, 74 women with benign ovarian disease, and 98 normal, healthy controls.
“By demonstrating that these findings are reproducible, Ciphergen hopes to advance these markers beyond the clinical validation process and into clinical trials,” says Eric T. Fung, M.D., Ph.D., CSO.